Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 3/20 | 0.36 |
| ▸ | CTSB | P07858 | 3/20 | 0.36 |
| ▸ | CTSH | P09668 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392982 | 1.00 | KMT2A (0.39) | KMT2AALDH1A1LTA4HCTSKTSHR | |
| SCHEMBL3335506 | 0.85 | LTA4H (0.43) | KMT2AALDH1A1LTA4HCTSKCTSL | |
| SCHEMBL3335513 | 0.85 | LTA4H (0.43) | KMT2AALDH1A1LTA4HCTSKCTSL | |
| Potassium Ion SCHEMBL392020 | 0.83 | ALDH1A1 (0.36) | KMT2AALDH1A1LTA4HCTSKCTSL | |
| SCHEMBL4244240 | 0.80 | ALDH1A1 (0.41) | KMT2AALDH1A1LTA4HCTSKTSHR | |
| SCHEMBL3130298 | 0.79 | ALDH1A1 (0.39) | KMT2AALDH1A1LTA4HCTSKTSHR | |
| SCHEMBL3129997 | 0.79 | ALDH1A1 (0.39) | KMT2AALDH1A1LTA4HCTSKTSHR | |
| SCHEMBL1176986 | 0.79 | LTA4H (0.46) | KMT2AALDH1A1LTA4HCTSKTSHR | |
| SCHEMBL389670 | 0.79 | ALDH1A1 (0.40) | KMT2AALDH1A1LTA4HCTSKTSHR | |
| SCHEMBL1176985 | 0.79 | LTA4H (0.46) | KMT2AALDH1A1LTA4HCTSKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969367-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969370-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140329845-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8703791-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140031380-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130345466-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8492399-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8486958-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130065916-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130035510-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-8324236-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8318765-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120088834-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088787-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8106232-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8101794-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100144881-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035510-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | KMT2A 2107/4885ALDH1A1 601/4885LTA4H 1258/4885 |
| US-20120088787-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | KMT2A 2107/4885ALDH1A1 601/4885LTA4H 1258/4885 |
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | KMT2A 2107/4885ALDH1A1 601/4885LTA4H 1258/4885 |
| US-20130345466-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | OPRM1, OPRK1, OPRL1 | KMT2A 2248/4885ALDH1A1 1569/4885LTA4H 1815/4885 |
| US-20130065916-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | OPRM1, OPRK1, OPRL1 | KMT2A 2248/4885ALDH1A1 1569/4885LTA4H 1815/4885 |
| US-20120088834-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | OPRM1, OPRK1, OPRL1 | KMT2A 2248/4885ALDH1A1 1569/4885LTA4H 1815/4885 |
| US-20140329845-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | KMT2A 2107/4885ALDH1A1 601/4885LTA4H 1258/4885 |
| US-20100144881-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | OPRM1, OPRK1, OPRL1 | KMT2A 2248/4885ALDH1A1 1569/4885LTA4H 1815/4885 |
| US-20140031380-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | KMT2A 2107/4885ALDH1A1 601/4885LTA4H 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.